nach oben

Current Treatment Options in Gastroenterology

Erschienen in:

29.10.2020 | Pancreas (C Forsmark, Section Editor)

Drug-Induced Pancreatic Injury (DIPI): Redefining Drug-Induced Pancreatitis in Adult and Pediatric Populations

verfasst von: Monique T. Barakat, MD, PhD, Emory M. Manten, MD, Sohail Z. Husain, MD, Jodie A. Barkin, MD

Erschienen in: Current Treatment Options in Gastroenterology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

Drug-induced pancreatitis is the second most common cause of acute pancreatitis (AP) in children and ranks as the third in adults. The aims of this targeted review are to provide a basis for conceptualizing drug-induced pancreatic injury (DIPI), to highlight specific drugs that are common or emerging risk factors, and to suggest a framework for future studies of DIPI.

Recent findings

We challenge the traditional notion of diagnosing a drug exposure as the etiology of pancreatitis only after other etiologies could not be identified. Instead, we propose rethinking the disease process as a continuum of pancreatic injury due to drug exposure that can be concomitant with other risk factors.

Summary

We favor a shift to use of the term drug-induced pancreatic injury (DIPI). There is a need to better characterize DIPI and to probe the mechanisms underlying the various types of DIPI, for the safer use of the DIPI inducing drugs by thwarting the adverse event of pancreatitis.

Park A, Latif SU, Shah AU, Tian J, Werlin S, Hsiao A, et al. Changing referral trends of acute pancreatitis in children: a 12-year single-center analysis. J Pediatr Gastroenterol Nutr. 2009;49:316–22.PubMedPubMedCentral

Balani AR, Grendell JH. Drug-induced pancreatitis : incidence, management and prevention. Drug Saf. 2008;31:823–37.PubMed

Andersen V, Sonne J, Andersen M. Spontaneous reports on drug-induced pancreatitis in Denmark from 1968 to 1999. Eur J Clin Pharmacol. 2001;57:517–21.PubMed

Lankisch PG, Droge M, Gottesleben F. Drug induced acute pancreatitis: incidence and severity. Gut. 1995;37:565–7.PubMedPubMedCentral

Vinklerova I, Prochazka M, Prochazka V, et al. Incidence, severity, and etiology of drug-induced acute pancreatitis. Dig Dis Sci. 2010;55:2977–81.PubMed

Sweeny KF, Lin TK, Nathan JD, Denson LA, Husain SZ, Hornung L, et al. Rapid progression of acute pancreatitis to acute recurrent pancreatitis in children. J Pediatr Gastroenterol Nutr. 2019;68:104–9.PubMedPubMedCentral

•• Bai HX, Ma MH, Orabi AI, et al. Novel characterization of drug-associated pancreatitis in children. J Pediatr Gastroenterol Nutr. 2011;53:423–8.This is the first study, to our knowledge, to define drug-associated pancreatitis as being non-mutually exclusive with other risk factors for pancreatitis, and thus, the study paved the way for a novel method for conceptualizing drug-induced pancreatitis injury (DIPI).PubMedPubMedCentral

Whitcomb DC, Yadav D, Adam S, Hawes RH, Brand RE, Anderson MA, et al. Multicenter approach to recurrent acute and chronic pancreatitis in the United States: the North American Pancreatitis Study 2 (NAPS2). Pancreatology. 2008;8:520–31.PubMedPubMedCentral

• Schwarzenberg SJ, Uc A, Zimmerman B, et al. Chronic pancreatitis: pediatric and adult cohorts show similarities in disease Progress despite different risk factors. J Pediatr Gastroenterol Nutr. 2019;68:566–73 This study combines data from two large pediatric and adult chronic pancreatitis registries to compare phenotypic differences between the two age groups.PubMedPubMedCentral

10.

Nakashima Y, Howard JM. Drug-induced acute pancreatitis. Surg Gynecol Obstet. 1977;145:105–9.PubMed

11.

• Badalov N, Baradarian R, Iswara K, et al. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol. 2007;5:648–61 quiz 644.The Badalov classification schema described in this paper for drug-induced pancreatitis is commonly used in clinical practice.PubMed

12.

•• Simons-Linares CR, Elkhouly MA, Salazar MJ. Drug-induced acute pancreatitis in adults: an update. Pancreas. 2019;48:1263–73 This article comprehensively chronicles causes of drug-induced pancreatic injury with appraisal and detailed synopsis of published evidence to date on multiple causes of drug-induced pancreatic injury.PubMed

13.

Tenner S. Drug induced acute pancreatitis: does it exist? World J Gastroenterol. 2014;20:16529–34.PubMedPubMedCentral

14.

Zheng J, Yang QJ, Dang FT, Yang J. Drug-induced pancreatitis: an update. Arab J Gastroenterol. 2019;20:183–8.PubMed

15.

Wolfe D, Kanji S, Yazdi F, Barbeau P, Rice D, Beck A, et al. Drug induced pancreatitis: a systematic review of case reports to determine potential drug associations. PLoS One. 2020;15:e0231883.PubMedPubMedCentral

16.

Bermejo F, Lopez-Sanroman A, Taxonera C, et al. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther. 2008;28:623–8.PubMed

17.

Rasmussen HH, Fonager K, Sorensen HT, et al. Risk of acute pancreatitis in patients with chronic inflammatory bowel disease. A Danish 16-year nationwide follow-up study. Scand J Gastroenterol. 1999;34:199–201.PubMed

18.

Weber P, Seibold F, Jenss H. Acute pancreatitis in Crohn's disease. J Clin Gastroenterol. 1993;17:286–91.PubMed

19.

Srinath AI, Gupta N, Husain SZ. Probing the Association of Pancreatitis in inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:465–75.PubMed

20.

Nogueira JR, Freedman MA. Acute pancreatitis as a complication of Imuran therapy in regional enteritis. Gastroenterology. 1972;62:1040–1.PubMed

21.

Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980;302:981–7.PubMed

22.

Ardizzone S, Maconi G, Sampietro GM, Russo A, Radice E, Colombo E, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology. 2004;127:730–40.PubMed

23.

Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995;37:674–8.PubMedPubMedCentral

24.

Teich N, Mohl W, Bokemeyer B, Bündgens B, Büning J, Miehlke S, et al. Azathioprine-induced acute pancreatitis in patients with inflammatory bowel diseases—a prospective study on incidence and severity. J Crohns Colitis. 2016;10:61–8.PubMed

25.

•• Heap GA, Weedon MN, Bewshea CM, et al. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet. 2014;46:1131–4 This is the first study, to our knowledge, to implicate susceptibility genes to DIPI, using the context of thiopurine-related DIPI.PubMedPubMedCentral

26.

Wilson A, Jansen LE, Rose RV, Gregor JC, Ponich T, Chande N, et al. HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2018;47:615–20.PubMed

27.

Lopez RN, Gupta N, Lemberg DA. Vedolizumab-associated pancreatitis in Paediatric ulcerative colitis: functional selectivity of the alpha4beta7integrin and MAdCAM-1 pathway? J Crohns Colitis. 2018;12:507–8.PubMed

28.

Werlang ME, Lewis MD, Bartel MJ. Tumor necrosis factor alpha inhibitor-induced acute pancreatitis. ACG Case Rep J. 2017;4:e103.PubMedPubMedCentral

29.

Batalden PB, Van Dyne BJ, Cloyd J. Pancreatitis associated with valproic acid therapy. Pediatrics. 1979;64:520–2.PubMed

30.

Walker RM, Smith GS, Barsoum NJ, Macallum GE. Preclinical toxicology of the anticonvulsant calcium valproate. Toxicology. 1990;63:137–55.PubMed

31.

Eisses JF, Criscimanna A, Dionise ZR, Orabi AI, Javed TA, Sarwar S, et al. Valproic acid limits pancreatic recovery after pancreatitis by inhibiting histone Deacetylases and preventing Acinar Redifferentiation programs. Am J Pathol. 2015;185:3304–15.PubMedPubMedCentral

32.

Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a pediatric oncology group study. Leukemia. 1999;13:335–42.PubMed

33.

• Wolthers BO, Frandsen TL, Abrahamsson J, et al. Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol. Leukemia. 2017;31:325–32 This study combined raw data from one and a half dozen international pediatric leukemia trial groups to confirm observations from previous series and systematic reviews that asparaginase-associated pancreatitis is a more severe form of pancreatitis than other etiologies and that it leads to substantial long-term endocrine dysfunction in a sizeable proportion of patients.PubMed

34.

Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33:2938–48.PubMedPubMedCentral

35.

Wolthers BO, Frandsen TL, Baruchel A, Attarbaschi A, Barzilai S, Colombini A, et al. Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study. Lancet Oncol. 2017;18:1238–48.PubMed

36.

Raja RA, Schmiegelow K, Frandsen TL. Asparaginase-associated pancreatitis in children. Br J Haematol. 2012;159:18–27.PubMed

37.

Oparaji JA, Rose F, Okafor D, Howard A, Turner RL, Orabi AI, et al. Risk factors for asparaginase-associated pancreatitis: a systematic review. J Clin Gastroenterol. 2017;51:907–13.PubMed

38.

Raja RA, Schmiegelow K, Henriksen BM, Leth Frandsen T. Serial ultrasound monitoring for early recognition of asparaginase associated pancreatitis in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2015;32:474–81.PubMed

39.

Raja RA, Schmiegelow K, Sorensen DN, et al. Asparaginase-associated pancreatitis is not predicted by hypertriglyceridemia or pancreatic enzyme levels in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2017;64:32–8.PubMed

40.

Ben Tanfous M, Sharif-Askari B, Ceppi F, Laaribi H, Gagne V, Rousseau J, et al. Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia. Clin Cancer Res. 2015;21:329–34.PubMed

41.

Liu QY, Abu-El-Haija M, Husain SZ, et al. Risk factors for rapid progression from acute recurrent to chronic pancreatitis in children: report from INSPPIRE. J Pediatr Gastroenterol Nutr. 2019;69:206–11.PubMedPubMedCentral

42.

Wolthers BO, Frandsen TL, Patel CJ, Abaji R, Attarbaschi A, Barzilai S, et al. Trypsin-encoding PRSS1-PRSS2 variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group report. Haematologica. 2019;104:556–63.PubMedPubMedCentral

43.

Abaji R, Gagne V, Xu CJ, et al. Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients. Oncotarget. 2017;8:43752–67.PubMedPubMedCentral

44.

Peng S, Gerasimenko JV, Tsugorka T, Gryshchenko O, Samarasinghe S, Petersen OH, et al. Calcium and adenosine triphosphate control of cellular pathology: asparaginase-induced pancreatitis elicited via protease-activated receptor 2. Philos Trans R Soc Lond Ser B Biol Sci. 2016;371:20150423.

45.

Peng S, Gerasimenko JV, Tsugorka TM, Gryshchenko O, Samarasinghe S, Petersen OH, et al. Galactose protects against cell damage in mouse models of acute pancreatitis. J Clin Invest. 2018;128:3769–78.PubMedPubMedCentral

46.

Mukherjee A, Ahmed N, Rose FT, Ahmad AN, Javed TA, Wen L, Bottino R, Xiao X, Kilberg MS, Husain SZ. Asparagine Synthetase Is Highly Expressed at Baseline in the Pancreas Through Heightened PERK Signaling. Cell Mol Gastroenterol Hepatol. 2020;9(1):1–13. https://doi.org/10.1016/j.jcmgh.2019.08.003

47.

Grant P, Gandhi P. A case of cannabis-induced pancreatitis. JOP. 2004;5:41–3.PubMed

48.

Barkin JA, Nemeth Z, Saluja AK, Barkin JS. Cannabis-induced acute pancreatitis: a systematic review. Pancreas. 2017;46:1035–8.PubMed

49.

Simons-Linares CR, Barkin JA, Wang Y, Jaiswal P, Trick W, Bartel MJ, et al. Is there an effect of Cannabis consumption on acute pancreatitis? Dig Dis Sci. 2018;63:2786–91.PubMed

50.

Njei B, Sharma P, McCarty TR, et al. Cannabis use is associated with increased risk of post-endoscopic retrograde Cholangiopancreatography pancreatitis: analysis of the US Nationwide Inpatient Sample Database, 2004-2014. Pancreas. 2018;47:1142–9.PubMed

51.

Dembinski A, Warzecha Z, Ceranowicz P, et al. Cannabinoids in acute gastric damage and pancreatitis. J Physiol Pharmacol. 2006;57(Suppl 5):137–54.PubMed

52.

Simons-Linares CR, Barkin JA, Jang S, Bhatt A, Lopez R, Stevens T, et al. The impact of Cannabis consumption on mortality, morbidity, and cost in acute pancreatitis patients in the United States: a 10-year analysis of the National Inpatient Sample. Pancreas. 2019;48:850–5.PubMed

53.

Lynch SM, Wu GY. Hepatitis C Virus: a review of treatment guidelines, cost-effectiveness, and access to therapy. J Clin Transl Hepatol. 2016;4:310–9.PubMedPubMedCentral

54.

Zhang J, Nguyen D, Hu KQ. Chronic Hepatitis C Virus infection: a review of current direct-acting antiviral treatment strategies. N Am J Med Sci (Boston). 2016;9:47–54.

55.

Chaudhari S, Park J, Anand BS, Pimstone NR, Dieterich DT, Batash S, et al. Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C. Dig Dis Sci. 2004;49:1000–6.PubMed

56.

Puri P, Anand AC, Saraswat VA, Acharya SK, Dhiman RK, Sarin SK, et al. Indian National Association for study of the liver (INASL) guidance for antiviral therapy against HCV infection in 2015. J Clin Exp Hepatol. 2015;5:221–38.PubMedPubMedCentral

57.

Karch FE, Lasagna L. Adverse drug reactions. A critical review. JAMA. 1975;234:1236–41.PubMed

58.

Uc A, Husain SZ. Pancreatitis in children. Gastroenterology. 2019;156:1969–78.PubMedPubMedCentral

59.

Arimone Y, Miremont-Salame G, Haramburu F, et al. Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions. Br J Clin Pharmacol. 2007;64:482–8.PubMedPubMedCentral

60.

Liu F, Jagannatha A, Yu H. Towards drug safety surveillance and Pharmacovigilance: current Progress in detecting medication and adverse drug events from electronic health records. Drug Saf. 2019;42:95–7.PubMedPubMedCentral

Titel: Drug-Induced Pancreatic Injury (DIPI): Redefining Drug-Induced Pancreatitis in Adult and Pediatric Populations
verfasst von: Monique T. Barakat, MD, PhD
Emory M. Manten, MD
Sohail Z. Husain, MD
Jodie A. Barkin, MD
Publikationsdatum: 29.10.2020
Verlag: Springer US
Erschienen in: Current Treatment Options in Gastroenterology / Ausgabe 4/2020
Print ISSN: 1092-8472
Elektronische ISSN: 1534-309X
DOI: https://doi.org/10.1007/s11938-020-00311-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Maintaining a Balanced Diet While Gluten-Free: Treatment Options

Genetic Gastric Cancer Risk Syndromes

Genetic Testing Use and Expectations in Early Onset Colorectal Cancer

Incorporating Frailty in the Treatment Program of Elderly Patients with Gastrointestinal Disease

Managing Gastrointestinal Complications in Patients With Systemic Sclerosis